Actimed Therapeutics Achieves Major Corporate Milestone - Initiation of first clinical study of new salt of S-pindolol (ACM-001.1)

Actimed Therapeutics Achieves Major Corporate Milestone - Initiation of first clinical study of new salt of S-pindolol (ACM-001.1)

• Actimed Therapeutics initiates the company’s first clinical study of the pharmacokinetics and pharmacodynamics (PK/PD) for a new salt of S-pindolol (ACM-001.1)
• This study is a prelude to the commencement of a Phase 2b clinical programme in patients
• ACM-001.1 has the potential to become the first globally approved drug to treat cancer cachexia

London, UK - 14 December 2021. Actimed Therapeutics Ltd announces that following regulatory approval from the UK Regulatory Agency, it has commenced a clinical study in healthy subjects to evaluate the PK and PD of its lead compound, ACM-001.1, a new salt of S-pindolol that is under development as a treatment for cancer cachexia.

The study will be conducted in healthy subjects in two parts. It will compare ACM-001.1 to pindolol and will investigate both single and multiple dose PK and assess a range of doses of ACM-001.1.

Data from the study are expected in the first half of 2022 and will be used to inform the Phase 2b programme which is planned for late 2022.

Robin Bhattacherjee, Actimed CEO, commented: “This is an exciting time in the development of our new salt form of S-pindolol. We have worked hard on the development of this formulation over the last 2 years given the considerable benefits it delivers including improved stability, scalability for commercial manufacture and the potential for significantly extended patent life. The PK/PD study is a key clinical development milestone towards our ultimate aim of securing the first global approval for the treatment of cancer cachexia, a hugely under-served disease which is estimated to affect 50-80% of all cancer patients.”